Treatment with the IL-1β inhibitor canakinumab does not improve the likelihood of survival without invasive mechanical ventilation among hospitalized patients with severe COVID-19 and systemic hyperinflammation, suggest findings from the CAN-COVID trial.
UK research suggests there is a disparity between humoral and cellular immune responses to the first dose of the Pfizer–BioNTech COVID-19 vaccine in people on methotrexate monotherapy for psoriasis.
Rheumatoid arthritis patients are more likely than healthy controls to require both doses of vaccines against SARS-CoV-2 in order to mount an adequate immune response, researchers report.
